倍他乐克与通心络联合治疗冠心病心绞痛的临床分析  

Clinical analysis of betaloc and Tongxinluo in combined therapy for coronary heart disease angor pectoris

作　　者：郭杰 

机构地区：[1]迎博社区卫生服务中心,200125

出　　处：《中国实用医药》2016年第33期120-121,共2页China Practical Medicine

摘　　要：目的探究分析酒石酸美托洛尔片(倍他乐克)与通心络联合治疗冠心病心绞痛的临床疗效。方法 300例冠心病心绞痛患者,随机分为对照组(采用常规临床治疗)与观察组(在常规治疗的基础上采用倍他乐克与通心络联合治疗),各150例。比较两组治疗效果及不良反应。结果观察组患者的总有效率为94.67%,高于对照组的86.00%,差异具有统计学意义(P<0.05)。观察组患者的不良反应发生率为3.33%,低于对照组的12.00%,差异具有统计学意义(P<0.05)。结论采用倍他乐克与通心络联合治疗冠心病心绞痛的效果显著,有效降低不良反应发生率,值得推广。Objective To investigate and analyze clinical effect by metoprolol tartrate tablets（betaloc）combined with Tongxinluo in the treatment of coronary heart disease angor pectoris. Methods A total of 300 patients with coronary heart disease angor pectoris were randomly divided into control group（received conventional clinical therapy）and observation group（received additional betaloc combined with Tongxinluo to conventional therpay）, with 150 cases in each group. Curative effects and adverse reactions were compared between the two groups. Results The observation group had higher total effective rate as 94.67% than 86.00% in the control group, and the difference had statistical significance（P〈0.05）. The observation group had incidence of adverse reactions as 3.33%, which was lower than 12.00% in the control group, and their difference had statistical significance（P〈0.05）. Conclusion Implement of betaloc and Tongxinluo in combined therapy for coronary heart disease angor pectoris shows excellent effect. This method can effectively reduce incidence of adverse reactions, and it is worth promoting.

关 键 词：酒石酸美托洛尔片 通心络 冠心病心绞痛 联合治疗 

分 类 号：R541.4[医药卫生—心血管疾病]